Leukemia, Myeloid, Acute: all 3,035 studies
Page 8 of 31. Open to participants first (746), then studies with results posted, then the rest; newest registration first within each.
- Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic SyndromeRecruitingNCT03661307Phase 1/2
- Pilot Imaging Study of LeukemiaRecruitingNCT03633955Phase 1
- Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing ChemotherapyRecruitingNCT03630991Phase 1
- Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid LeukemiaRecruitingNCT03629171Phase 2
- Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood CancersRecruitingNCT03589729Phase 2
- Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid LeukemiaRecruitingNCT03586609Phase 2
- Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant CyclophosphamideRecruitingNCT03533816Phase 1
- A Prospective Randomized Comparison of HDAC Vs AD in the Induction Chemothrapy for AML.Enrolling by invitationNCT03507842Phase 3
- Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic MalignanciesRecruitingNCT03471260Phase 1/2
- Incidence of Neutropenic Enterocolitis Study in Acute Myeloid Leukemia Patients During Intensive TherapyRecruitingNCT03450512
- Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic SyndromeRecruitingNCT03383575Phase 2
- HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell TransplantRecruitingNCT03326921Phase 1
- Myeloablative Allo HSCT With Related or Unrelated Donor for Heme DisordersRecruitingNCT03314974Phase 2
- Expanded Natural Killer Cells Following Haploidentical HSCT for AML/MDSRecruitingNCT03300492Phase 1/2
- CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDSRecruitingNCT03291444Phase 1
- Multi-CAR T Cell Therapy for Acute Myeloid LeukemiaNot yet recruitingNCT03222674Phase 1/2
- Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid LeukemiaRecruitingNCT03214562Phase 1/2
- Clinical AML Registry and Biomaterial Database of the Study Alliance Leukemia (SAL)RecruitingNCT03188874
- 211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute LeukemiaRecruitingNCT03128034Phase 1/2
- Expanded Access to VenetoclaxAvailableNCT03123029
- SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)RecruitingNCT03113643Phase 1
- Efficacy and Safety of ATO Plus ATRA in Nucleophosmin-1 Mutated Acute Myeloid LeukemiaEnrolling by invitationNCT03031249Phase 1/2
- A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or LymphomaRecruitingNCT03017820Phase 1
- Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AMLRecruitingNCT02781883Phase 2
- Personalized NK Cell Therapy in CBTRecruitingNCT02727803Phase 2
- KIR Favorable Mismatched Haplo Transplant and KIR Polymorphism in ALL/AML/MDS Allo-HCT ChildrenEnrolling by invitationNCT02646839Phase 2
- Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid TumorsRecruitingNCT02508038Phase 1
- Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CRRecruitingNCT02416388Phase 2/3
- Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...RecruitingNCT02390752Phase 1
- PET/MRI, 18F-FDG PET/CT and Whole Body MRI in Finding Extramedullary Myeloid Leukemia in Patients With Newly Diagnosed Acute Myeloid LeukemiaRecruitingNCT02390635Phase 1
- Cancer Experience Registry (CER) for Cancer Patients and CaregiversRecruitingNCT02333604
- Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical OutcomeRecruitingNCT02269592
- Multi-institutional Prospective Research of Expanded Multi-antigen Specifically Oriented Lymphocytes for the Treatment of VEry High Risk Hematopoietic MalignanciesRecruitingNCT02203903Phase 1
- HSCT for Patients With Fanconi Anemia Using Risk-Adjusted ChemotherapyRecruitingNCT02143830Phase 2
- Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid LeukemiaRecruitingNCT02115295Phase 2
- Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 MutationRecruitingNCT02074839Phase 1
- The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative RegimenRecruitingNCT01890486
- Expanded Access to T-cell Depleted Haplo-Identical Stem Cells for Patients Receiving Haplo-Identical and Unrelated Cord Blood TransplantsAvailableNCT01881334
- Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)RecruitingNCT01515527Phase 2
- A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)RecruitingNCT01351545
- Monitoring Minimal Residual Disease of Patients With Acute Myelogenous Leukemia or High Grade Myelodysplastic SyndromeRecruitingNCT01311258
- Registry Study on Patient Characteristics, Biological Disease Profile and Clinical Outcome in Acute Myeloid Leukemia and Related Neoplasms - The Biology and Outcome (BiO)-ProjectRecruitingNCT01252485
- Characterization of the Mechanisms of Resistance to AzacitidineRecruitingNCT01210274
- Registry of Older Patients With CancerRecruitingNCT01137825
- Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic CancerRecruitingNCT01137643
- Biology Studies of Hematologic CancersEnrolling by invitationNCT00923442
- Luveltamab Tazevibulin (STRO-002) in Infants and Children < 12 Years of Age With Relapsed/Refractory CBFA2T3::GLIS2 AMLTerminatedNCT06679582Phase 1/2Results posted
- A Study to Investigate Natural Killer Cell Engager (SAR443579) With Different Agents in Participants With Hematological MalignanciesTerminatedNCT06508489Phase 1/2Results posted
- Music Therapy in Acute Leukemia Patients With FatigueCompletedNCT06286332Not applicableResults posted
- Electronic Health Mindfulness-based Music Therapy Intervention for Patients Undergoing Allogeneic Stem Cell TransplantationCompletedNCT05968963Not applicableResults posted
- Eltanexor (KPT-8602) With Inqovi (Decitabine-Cedazuridine) in High-Risk Myelodysplastic SyndromesTerminatedNCT05918055Phase 1/2Results posted
- A Study of GDX012 in Adults With Relapsed or Refractory Acute Myeloid LeukemiaTerminatedNCT05886491Phase 1/2Results posted
- Decitabine and Cedazuridine in Combination With Venetoclax for the Treatment of Patients Who Have Relapsed Acute Myeloid Leukemia After Donor Stem Cell TransplantTerminatedNCT05799079Phase 2Results posted
- A Safety, Tolerability and Efficacy Study of NC525 in Subjects With Advanced Myeloid NeoplasmsTerminatedNCT05787496Phase 1Results posted
- Study of CPX-351 (VYXEOS) in Individuals < 22 Years With Secondary Myeloid NeoplasmsActive, not recruitingNCT05656248Phase 2Results posted
- Vyxeos for Induction of Low- or Intermediate-risk.Active, not recruitingNCT05599360Phase 2Results posted
- Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based TherapyCompletedNCT05583552Phase 2Results posted
- Post-transplant Flotetuzumab for AMLCompletedNCT05506956Phase 1Results posted
- A Study of Siremadlin Alone and in Combination With Donor Lymphocyte Infusion in Acute Myeloid Leukemia Post-allogeneic Stem Cell TransplantTerminatedNCT05447663Phase 1/2Results posted
- A Phase 1, Open Label Study of Intravenous GSK3745417 to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Determine RP2D & Schedule in Participants With Relapsed or Refractory Myeloid Malignancies Including AML and HR MDSTerminatedNCT05424380Phase 1Results posted
- A Patient-Centered Communication Tool (UR-GOAL) Versus Usual Care for Older Patients With Acute Myeloid Leukemia, Their Caregivers, and Their OncologistsCompletedNCT05335369Not applicableResults posted
- Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic MalignanciesActive, not recruitingNCT05316701Phase 3Results posted
- Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AMLTerminatedNCT05275439Phase 1Results posted
- Haploidentical Hematopoietic Cell Transplantation Using TCR Alpha/Beta and CD19 DepletionActive, not recruitingNCT05236764Not applicableResults posted
- A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Japanese Participants With Acute Myeloid Leukemia (AML) in Complete RemissionActive, not recruitingNCT05197426Phase 2Results posted
- A Study to Assess the Effect of CC-95251 in Participants With Acute Myeloid Leukemia and Myelodysplastic SyndromesTerminatedNCT05168202Phase 1Results posted
- Latin American Real-world Study in Acute LeukemiaCompletedNCT05166135Results posted
- Highest Dose of Uproleselan in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Mixed Phenotype Acute Leukemia Relapsed or Refractory That Expresses E-selectin Ligand on the Cell MembraneActive, not recruitingNCT05146739Phase 1Results posted
- Off-the-shelf NK Cells + SCT for Myeloid MalignanciesCompletedNCT05115630Phase 2Results posted
- Study of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid LeukemiaTerminatedNCT05079230Phase 3Results posted
- Study Investigating NTLA-5001 in Subjects With Acute Myeloid LeukemiaTerminatedNCT05066165Phase 1/2Results posted
- Removing Transfusion Dependence as a Barrier to Hospice EnrollmentCompletedNCT05063591Not applicableResults posted
- A Study to Evaluate MK-0482 for Relapsed/Refractory Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML) (MK-0482-002)TerminatedNCT05038800Phase 1Results posted
- A Study to Evaluate Lanraplenib (LANRA) in Combination With Gilteritinib in Participants With FLT3-mutated Relapsed or Refractory Acute Myeloid Leukemia (AML)TerminatedNCT05028751Phase 1/2Results posted
- A Study of E7820 in People With Bone Marrow (Myeloid) CancersCompletedNCT05024994Phase 2Results posted
- Entospletinib Plus Intensive Induction/Consolidation Chemotherapy in Newly Diagnosed NPM1-mutated AMLTerminatedNCT05020665Phase 3Results posted
- High- Fiber/ Low-fat Diet for Prevention of Recurrent Clostridioides Difficile Infection in OncologyCompletedNCT04940468Not applicableResults posted
- KPT-9274 in Patients With Relapsed and Refractory Acute Myeloid LeukemiaCompletedNCT04914845Phase 1Results posted
- Accelerated Dose Schedule of Cytarabine Consolidation Therapy for Older Patients With Acute Myeloid Leukemia (AML) in Complete RemissionTerminatedNCT04914676Phase 2Results posted
- Tamibarotene Plus Venetoclax/Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)TerminatedNCT04905407Phase 2Results posted
- Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1TerminatedNCT04874194Phase 1/2Results posted
- Continuation Study of B1371019(NCT03416179) and B1371012(NCT02367456) Evaluating Azacitidine With Or Without Glasdegib In Patients With Previously Untreated AML, MDS or CMMLCompletedNCT04842604Phase 3Results posted
- GEN3014 Trial in Relapsed or Refractory Hematologic MalignanciesTerminatedNCT04824794Phase 1/2Results posted
- Testing Oral Decitabine and Cedazuridine (ASTX727) in Combination With Venetoclax for Higher-Risk Acute Myeloid Leukemia PatientsActive, not recruitingNCT04817241Phase 1/2Results posted
- Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin and Cytarabine Liposome) in Newly Diagnosed Acute Myeloid Leukemia With Myelodysplastic Syndrome-Related ChangesActive, not recruitingNCT04802161Phase 2Results posted
- Study of KITE-222 in Participants With Relapsed/Refractory Acute Myeloid LeukemiaTerminatedNCT04789408Phase 1Results posted
- Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been TreatedTerminatedNCT04778397Phase 3Results posted
- A Study of HMPL-306 in Advanced Hematological Malignancies With mIDHTerminatedNCT04764474Phase 1Results posted
- MGTA-145 + Plerixafor in the Mobilization of HSCs for Allogeneic Transplant in Hematologic MalignanciesTerminatedNCT04762875Phase 2Results posted
- DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic LeukemiaTerminatedNCT04752163Phase 1/2Results posted
- A Telehealth Advance Care Planning Intervention for Older Patients With Acute Myeloid Leukemia and Myelodysplastic SyndromeCompletedNCT04745676Not applicableResults posted
- FT538 in Combination With Daratumumab in AML Acute Myeloid LeukemiaCompletedNCT04714372Phase 1Results posted
- ADCT-301 in Patients With R/R AML, MDS, or MDS/MPNTerminatedNCT04639024Phase 2Results posted
- Phase I/II Trial of S64315 Plus Azacitidine in Acute Myeloid LeukaemiaCompletedNCT04629443Phase 1/2Results posted
- A Patient-centered Communication Tool (UR-GOAL) for Older Patients With Acute Myeloid Leukemia, Their Caregivers, and Their OncologistsCompletedNCT04625413Not applicableResults posted
- Sabatolimab as a Treatment for Patients With Acute Myeloid Leukemia and Presence of Measurable Residual Disease After Allogeneic Stem Cell Transplantation.TerminatedNCT04623216Phase 1/2Results posted
- Flotetuzumab for Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Following Allogeneic Hematopoietic Cell Transplantation (Allo-HCT)TerminatedNCT04582864Phase 2Results posted
- Dociparstat in Combination With Standard Chemotherapy for the Treatment of Acute Myeloid LeukemiaTerminatedNCT04571645Phase 3Results posted
- RN-Led Palliative and Supportive Care InterventionCompletedNCT04570709Not applicableResults posted
- Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic SyndromeCompletedNCT04487106Phase 2Results posted